Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.

Zoryve is also available in a 0.3% cream formulation for the treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. References: ...

TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp ...